James N Kochenderfer

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 14

Top Topics

Multiple Myeloma

Mesenchymal Stem Cells

Acute Lymphoblastic Leukemia

Top Venues

Nature medicine

Nature reviews. Clinical oncology

Nature communications

Nature reviews. Immunology

This page only lists publications with an associated author ORCID identifier.

Publications

Jennifer N Brudno, James N Kochenderfer
Current understanding and management of CAR T cell-associated toxicities. Nature reviews. Clinical oncology (2024)
Jennifer N Brudno, James N Kochenderfer
Current understanding and management of CAR T cell-associated toxicities. Nature reviews. Clinical oncology 21 (7) (2024)
James B Chung, Jennifer N Brudno, Dominic Borie, James N Kochenderfer
Chimeric antigen receptor T cell therapy for autoimmune disease. Nature reviews. Immunology (2024)
Jennifer N Brudno, James N Kochenderfer
Off-the-shelf CAR T cells for multiple myeloma. Nature medicine 29 (2) (2023)
Jennifer N Brudno, James N Kochenderfer
Off-the-shelf CAR T cells for multiple myeloma. Nature medicine (2023)
Yi Lin, Noopur S Raje, Jesus G Berdeja, David S Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V Maus, Monica Massaro, Fabio Petrocca, Ashish Yeri, Olivia Finney, Andrea Caia, Zhihong Yang, Nathan Martin, Timothy B Campbell, Julie Rytlewski, Jaymes Fuller, Kristen Hege, Nikhil C Munshi, James N Kochenderfer
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nature medicine (2023)
Kathryn M Cappell, James N Kochenderfer
Long-term outcomes following CAR T cell therapy: what we know so far. Nature reviews. Clinical oncology (2023)
Jennifer N Brudno, James N Kochenderfer
Off-the-shelf CAR T cells for multiple myeloma. Nature medicine 29 (2) (2023)
Jennifer N Brudno, James N Kochenderfer
Off-the-shelf CAR T cells for multiple myeloma. Nature medicine 29 (2) (2023)
Kathryn M Cappell, James N Kochenderfer
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nature reviews. Clinical oncology 18 (11) (2021)
Lekha Mikkilineni, James N Kochenderfer
CAR T cell therapies for patients with multiple myeloma. Nature reviews. Clinical oncology 18 (2) (2020)
Jennifer N Brudno, Norris Lam, Danielle Vanasse, Yueh-Wei Shen, Jeremy J Rose, John Rossi, Allen Xue, Adrian Bot, Nathalie Scholler, Lekha Mikkilineni, Mark Roschewski, Robert Dean, Raul E Cachau, Philippe Youkharibache, Rashmika Patel, Brenna Hansen, David F Stroncek, Steven A Rosenberg, Ronald E Gress, James N Kochenderfer
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nature medicine 26 (2) (2020)
Norris Lam, Nathan D Trinklein, Benjamin Buelow, George H Patterson, Namrata Ojha, James N Kochenderfer
Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nature communications 11 (1) (2020)
Norris Lam, Nathan D Trinklein, Benjamin Buelow, George H Patterson, Namrata Ojha, James N Kochenderfer
Author Correction: Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nature communications 11 (1) (2020)